Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
EMUC 2026
Risk of major adverse cardiovascular events (MACE) with darolutamide versus enzalutamide in patients with advanced prostate cancer: A real-world observational study
- Darolutamide was associated with up to 19% and 15% lower risks of 3-point MACE (non-fatal MI, non-fatal stroke, or CV death) and 4-point MACE (plus angina or coronary revascularization), respectively, than enzalutamide in advanced prostate cancer, including mHSPC, where reductions were up to 27% (3-point MACE) and 20% (4-point MACE)
- EAU guidelines identify darolutamide as a preferred option for patients with CV comorbidities;1 ESC guidelines report the lowest ARPI-related CV toxicity with darolutamide2
- CV-related death is the most common noncancer cause of death among patients with prostate cancer
- Darolutamide was associated with lower risk of 3-point and 4-point MACE compared with enzalutamide
- Consider different CV impact from systemic treatment when selecting and managing patients with advanced prostate cancer (nmCRPC and mHSPC)
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
